Item 1.01 Entry into a Material Definitive Agreement.
On March 21, 2021 Todos Medical Ltd. (the “Company”) entered into a Waiver Agreement with Yozma Global Genomic Fund I (“Yozma”) whereby Yozma waived Section 4.22 of the Securities Purchase Agreement between the Company and Yozma dated January 22, 2021. As part of the waiver, Yozma agreed that it will not be entitled to designate anyone as its Board designee.
The foregoing description of the Waiver Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Waiver Agreement, a form of which is attached as Exhibit 10.1 to this Current Report on Form 8-K,and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
Pursuant to Section 5.5 of the Securities Purchase Agreement (the “Agreement”) dated January 22, 2021 between Todos Medical Ltd. and Yozma Global Genomic Fund 1 (“Yozma”), Yozma hereby waives Section 4.22 of the Agreement in perpetuity and agrees that it will not be entitled to designate anyone as its Board designee. Capitalized terms not defined herein shall have the meanings assigned to them in the Agreement.
Yozma Global Genomic Fund 1 By:/s/ Wonjae Lee Name:Wonjae Lee Title:Representative fund manager
Accepted and Acknowledged by: Todos Medical Ltd. By:/s/ Gerald Commissiong 3/21/2021